Beer Yaakov-Ness Ziona Mental Health Center, Tel Aviv University, Tel-Aviv, Israel.
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Curr Top Behav Neurosci. 2021;48:61-99. doi: 10.1007/7854_2020_152.
People with bipolar disorder (BD) all too often have suboptimal long-term outcomes with existing treatment options. They experience relapsing episodes of depression and mania and also have interepisodic mood and anxiety symptoms. We need to have a better understanding of the pathophysiology of BD if we are to make progress in improving these outcomes. This chapter will focus on the critical role of mitochondria in human functioning, oxidative stress, and the biological mechanisms of mitochondria in BD. Additionally, this chapter will present the evidence that, at least for some people, BD is a product of mitochondrial dysregulation. We review the modulators of mitochondria, the connection between current BD medication treatments and mitochondria, and additional medications that have theoretical potential to treat BD.
患有双相情感障碍 (BD) 的人,现有的治疗方案往往无法达到理想的长期效果。他们会反复发作抑郁和躁狂,还会间歇性地出现情绪和焦虑症状。如果我们要在改善这些结果方面取得进展,就需要更好地了解 BD 的病理生理学。本章将重点介绍线粒体在人体功能、氧化应激以及 BD 中线粒体的生物学机制中的关键作用。此外,本章还将提出证据表明,至少对某些人来说,BD 是线粒体失调的产物。我们回顾了线粒体的调节剂、当前 BD 药物治疗与线粒体之间的联系,以及具有治疗 BD 理论潜力的其他药物。